These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 35295914)

  • 1. Molnupiravir, favipiravir and other antiviral drugs with proposed potentials for management of COVID-19: a concern on antioxidant aspect.
    Yasri S; Wiwanitki V
    Int J Biochem Mol Biol; 2022; 13(1):1-4. PubMed ID: 35295914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences.
    Singla S; Goyal S
    Bull Natl Res Cent; 2022; 46(1):62. PubMed ID: 35287311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electron Donor-Acceptor Capacity of Selected Pharmaceuticals against COVID-19.
    Martínez A
    Antioxidants (Basel); 2021 Jun; 10(6):. PubMed ID: 34207391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of Goods Analysis Facilitates an Integrated Approach to Identifying Alternative Synthesis Methodologies for Lower Cost Manufacturing of the COVID-19 Antiviral Molnupiravir.
    Peterson C; Paria S; Deshpande A; Ahmad S; Harmon A; Dillon J; Laird T
    Gates Open Res; 2022; 6():8. PubMed ID: 35299948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetic Study of Antiviral Drugs in Patients with COVID-19].
    Irie K
    Yakugaku Zasshi; 2023; 143(3):239-241. PubMed ID: 36858556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uric Acid Elevation by Favipiravir, an Antiviral Drug.
    Mishima E; Anzai N; Miyazaki M; Abe T
    Tohoku J Exp Med; 2020 Jun; 251(2):87-90. PubMed ID: 32536670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favipiravir: A new and emerging antiviral option in COVID-19.
    Agrawal U; Raju R; Udwadia ZF
    Med J Armed Forces India; 2020 Oct; 76(4):370-376. PubMed ID: 32895599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
    Fischer WA; Eron JJ; Holman W; Cohen MS; Fang L; Szewczyk LJ; Sheahan TP; Baric R; Mollan KR; Wolfe CR; Duke ER; Azizad MM; Borroto-Esoda K; Wohl DA; Coombs RW; James Loftis A; Alabanza P; Lipansky F; Painter WP
    Sci Transl Med; 2022 Jan; 14(628):eabl7430. PubMed ID: 34941423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir?
    Clark NF; Taylor-Robinson AW; Heimann K
    Ther Adv Drug Saf; 2022; 13():20420986221107753. PubMed ID: 35898799
    [No Abstract]   [Full Text] [Related]  

  • 10. Two cases of novel coronavirus infection (COVID-19) with transient viral elevation using semi-quantitative real-time reverse transcription PCR and symptom relapse after completion of 10 days of favipiravir treatment.
    Tsuboi H; Kasamatsu Y; Matsubara S; Sasao A; Kunimitsu K; Munakata N; Ito T; Tsuchido Y; Yamawaki M; Fujita N
    J Infect Chemother; 2021 Jul; 27(7):1072-1075. PubMed ID: 33814353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review.
    Srinivasan K; Rao M
    Ther Adv Infect Dis; 2021; 8():20499361211063016. PubMed ID: 34881025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.
    Lee CC; Hsieh CC; Ko WC
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques.
    Guedj J; Piorkowski G; Jacquot F; Madelain V; Nguyen THT; Rodallec A; Gunther S; Carbonnelle C; Mentré F; Raoul H; de Lamballerie X
    PLoS Med; 2018 Mar; 15(3):e1002535. PubMed ID: 29584730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phytochemicals from Plant Foods as Potential Source of Antiviral Agents: An Overview.
    Behl T; Rocchetti G; Chadha S; Zengin G; Bungau S; Kumar A; Mehta V; Uddin MS; Khullar G; Setia D; Arora S; Sinan KI; Ak G; Putnik P; Gallo M; Montesano D
    Pharmaceuticals (Basel); 2021 Apr; 14(4):. PubMed ID: 33921724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New anti-viral drugs for the treatment of COVID-19 instead of favipiravir.
    Aktaş A; Tüzün B; Aslan R; Sayin K; Ataseven H
    J Biomol Struct Dyn; 2021 Nov; 39(18):7263-7273. PubMed ID: 32783586
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Al-Moubarak E; Sharifi M; Hancox JC
    Front Cardiovasc Med; 2021; 8():645172. PubMed ID: 34017865
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic.
    Vallianou NG; Tsilingiris D; Christodoulatos GS; Karampela I; Dalamaga M
    Metabol Open; 2021 Jun; 10():100096. PubMed ID: 34056571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Antiviral Therapy in Highly-Transmissible Variants of SARS-CoV-2: A Modeling and Simulation Study.
    Schöning V; Kern C; Chaccour C; Hammann F
    Front Pharmacol; 2022; 13():816429. PubMed ID: 35222030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics.
    Wang X; Sacramento CQ; Jockusch S; Chaves OA; Tao C; Fintelman-Rodrigues N; Chien M; Temerozo JR; Li X; Kumar S; Xie W; Patel DJ; Meyer C; Garzia A; Tuschl T; Bozza PT; Russo JJ; Souza TML; Ju J
    bioRxiv; 2021 Jul; ():. PubMed ID: 34312622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022.
    Wang L; Berger NA; Davis PB; Kaelber DC; Volkow ND; Xu R
    medRxiv; 2022 Jun; ():. PubMed ID: 35794889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.